Table 3. Predictive values of baseline, interim and end-of-treatment PET/CT.
| PPV (%) | NPV (%) | Se (%) | Sp (%) | PLR | NLR | ACC (%) | |
|---|---|---|---|---|---|---|---|
| Baseline SUVmax (n = 47) | |||||||
| PFS | 52.4 | 69.2 | 57.9 | 64.3 | 1.62 | 0.65 | 61.7 |
| OS | 42.9 | 92.3 | 81.8 | 66.7 | 2.46 | 0.27 | 70.2 |
| Baseline WBMTV (n = 47) | |||||||
| PFS | 75.0 | 77.4 | 63.2 | 85.7 | 4.42 | 0.43 | 76.6 |
| OS | 43.8 | 87.1 | 63.6 | 75.0 | 2.55 | 0.48 | 72.3 |
| Baseline WBTLG (n = 47) | |||||||
| PFS | 65.4 | 90.5 | 89.5 | 67.9 | 2.78 | 0.16 | 76.6 |
| OS | 38.5 | 95.2 | 90.9 | 55.6 | 2.05 | 0.16 | 63.8 |
| I-PET (n = 34) | |||||||
| PFS | 66.7 | 78.9 | 71.4 | 75.0 | 2.86 | 0.38 | 73.7 |
| OS | 46.7 | 89.5 | 77.8 | 68.0 | 2.43 | 0.33 | 70.6 |
| E-PET (n = 28) | |||||||
| PFS | 66.7 | 73.7 | 54.5 | 82.4 | 3.10 | 0.55 | 71.4 |
| OS | 55.6 | 84.2 | 62.5 | 80.0 | 3.13 | 0.47 | 75.0 |
PPV, positive predictive value; NPV, negative predictive value; Se, sensitivity; Sp, specificity; PLR, positive likelihood ratio, NLR, negative likelihood ratio; ACC, accuracy; SUVmax, maximum standardized uptake value; WBMTV, whole-body metabolic tumour volume; WBTLG, whole-body total lesion glycolysis; I-PET, interim PET/CT; E-PET, end-of-treatment PET/CT; PFS, progression-free survival; OS, overall survival.